Anebulo Pharmaceuticals, Inc.
ANEB
$2.30
-$0.01-0.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.44% | -7.51% | -26.96% | -24.47% | -23.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.01% | -13.00% | -24.92% | -30.20% | -29.49% |
| Operating Income | -11.01% | 13.00% | 24.92% | 30.20% | 29.49% |
| Income Before Tax | -3.45% | 17.73% | 26.92% | 31.72% | 30.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.45% | 17.73% | 26.92% | 31.72% | 30.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.45% | 17.73% | 26.92% | 31.72% | 30.09% |
| EBIT | -11.01% | 13.00% | 24.92% | 30.20% | 29.49% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 15.84% | 26.36% | 28.91% | 32.36% | 31.94% |
| Normalized Basic EPS | 15.85% | 26.38% | 28.90% | 32.36% | 31.92% |
| EPS Diluted | 15.84% | 26.36% | 28.91% | 32.36% | 31.94% |
| Normalized Diluted EPS | 15.85% | 26.38% | 28.90% | 32.36% | 31.92% |
| Average Basic Shares Outstanding | 31.20% | 16.87% | 2.46% | 1.03% | 2.96% |
| Average Diluted Shares Outstanding | 31.20% | 16.87% | 2.46% | 1.03% | 2.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |